Li Rong

Dr. Li Rong


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2017 in Pathology and Oncology Research
Verified
Journal Article
Closed access
PDF file
LRLi Rong
Li Rong
WHWei Huang
Wei Huang
STShangkun Tian
Shangkun Tian
XCXiangbo Chi
Xiangbo Chi
PZPan Zhao
Pan Zhao
FLFengfeng Liu
Fengfeng Liu

30 August 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
GLGuanyi Liao
Guanyi Liao
YXYuchen Xie
Yuchen Xie
HPHong Peng
Hong Peng
TLTianke Li
Tianke Li
XZXinsen Zou
Xinsen Zou
LRLi Rong
Li Rong
Nicotinamide mononucleotide (NMN), a crucial intermediate in NAD + synthesis, can rapidly transform into NAD + within the body after ingestion. NMN plays a pivotal role in several important biological processes, including energy metabolism, cellular aging, circadian rhythm regulation, DNA repair, chromatin remodeling, immunity, and inflammation. NMN has emerged as a key focus of research in the fields of biomedicine, health care, and food science. Recent years have witnessed extensive preclinical studies on NMN, offering valuable insights into the pathogenesis of age- and aging-related diseases. Given the sustained global research interest in NMN and the substantial market expectations for the future, here, we comprehensively review the milestones in research on NMN biotherapy over the past 10 years. Additionally, we highlight the current research on NMN in the field of digestive system diseases, identifying existing problems and challenges in the field of NMN research. The overarching aim of this review is to provide references and insights for the further exploration of NMN within the spectrum of digestive system diseases.

15 October 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
ZZZiyi Zhang
Ziyi Zhang
CPChangwei Peng
Changwei Peng
HPHong Peng
Hong Peng
YZYuanxia Zhu
Yuanxia Zhu
CHChenghu Huang
Chenghu Huang
LRLi Rong
Li Rong
Background: Hypertriglyceridemic acute pancreatitis (HTG-AP) is accompanied by significant metabolic abnormalities, but few studies have investigated whether a composite measure of this metabolic burden is associated with severe acute pancreatitis (SAP). The metabolic score for insulin resistance (METS-IR), derived from fasting glucose, high-density lipoprotein cholesterol, triglycerides, and body mass index, can be calculated from routinely available clinical data without requiring an insulin assay. However, its association with SAP in HTG-AP remains poorly characterized. Objective: This study investigates the association between admission METS-IR and SAP in patients with HTG-AP and assesses the robustness of this association through subgroup and sensitivity analyses. Methods: We retrospectively assembled a single-center cohort of 456 adults admitted with HTG-AP between January 2019 and July 2025. Logistic regression evaluated METS-IR as a continuous exposure and in quartiles. Restricted cubic splines, subgroup analyses, and sensitivity analyses were performed. Exploratory ROC analyses compared apparent discrimination with TyG, TyG-BMI, and BISAP. Results: SAP occurred in 78 of 456 patients (17.1%). Median METS-IR was 69.99 (IQR, 61.92–83.67) in the SAP group and 58.18 (IQR, 51.47–66.46) in the non-SAP group. In Model 3, each one-point increase in METS-IR was associated with higher odds of SAP (OR, 1.06; 95% CI, 1.04–1.08). After additional adjustment for TG, TG/HDL-C, and TyG, the estimate was attenuated (OR, 1.03; 95% CI, 0.997–1.064; P = 0.073). Apparent AUCs were 0.730 for METS-IR, 0.720 for TyG, and 0.758 for BISAP; neither paired comparison showed a statistically significant difference. In the three-category analysis, the METS-IR association was stronger for SAP vs. MAP than for MSAP vs. MAP. Conclusion: Higher admission METS-IR was independently associated with higher odds of SAP in patients with HTG-AP. METS-IR may provide a readily available measure of metabolic burden for early clinical assessment of patients with HTG-AP, although its clinical utility requires confirmation in prospective multicenter studies.